FDA Warns of Adverse Effects and Deaths Linked to Dog Arthritis Drug Librela

The medication, approved in 2023 to treat osteoarthritis in dogs, has been associated with thousands of health issues and fatalities, prompting an official alert to veterinarians.

• The FDA has issued a warning about Librela, a monoclonal antibody injection for dogs with osteoarthritis, citing over 3,600 reported cases of adverse effects between 2023 and March 2024.
• Reported side effects include seizures, ataxia, paresis, urinary incontinence, excessive thirst and urination, and in severe cases, death or euthanasia.
• Librela, manufactured by Zoetis, was approved by the FDA in May 2023 and has been administered to millions of dogs worldwide, with the company maintaining its safety and efficacy claims.
• Veterinarians are urged to report any adverse effects observed in dogs treated with Librela to Zoetis or directly to the FDA for further investigation.
• The FDA's alert follows growing concerns from pet owners, veterinarians, and online communities about the drug's safety, as well as calls for additional scrutiny and potential label updates.

3 Articles

Metro New York Post Newsweek